| 000 | 01756 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516020603.0 | ||
| 264 | 0 | _c20110722 | |
| 008 | 201107s 0 0 eng d | ||
| 022 | _a1096-0023 | ||
| 024 | 7 |
_a10.1016/j.cyto.2010.12.004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPranzatelli, Michael R | |
| 245 | 0 | 0 |
_aChemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS. _h[electronic resource] |
| 260 |
_bCytokine _cMar 2011 |
||
| 300 |
_a384-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenocorticotropic Hormone _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aB-Cell Activating Factor _xblood |
| 650 | 0 | 4 |
_aB-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aChemokine CXCL13 _xblood |
| 650 | 0 | 4 |
_aChemokines _xblood |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aCytokines _xblood |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoassay _xmethods |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xadministration & dosage |
| 650 | 0 | 4 |
_aImmunologic Factors _xadministration & dosage |
| 650 | 0 | 4 |
_aOpsoclonus-Myoclonus Syndrome _xblood |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTate, Elizabeth D | |
| 700 | 1 | _aTravelstead, Anna L | |
| 700 | 1 | _aVerhulst, Steven J | |
| 773 | 0 |
_tCytokine _gvol. 53 _gno. 3 _gp. 384-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.cyto.2010.12.004 _zAvailable from publisher's website |
| 999 |
_c20497163 _d20497163 |
||